Is Myo-inositol better than Metformin for treatment of PCOS Overweight Patients?

Abstract

Objective: In PCOS patients, the mean BMI was compared between Myo-inositol and Metformin. Methodology: This Randomized Control Trial was conducted at Department of Gynaecology and Obstetrics, P.A.E.C General Hospital, Islamabad, from May 24, 2017 to Nov 24, 2017. To choose a volunteer for the study, non-probability sequential sampling was utilized. All women diagnosed with PCOS having age between 15 and 40 were included in our study. There were two groups of participants: one group got myoinositol 1 gm twice a day, and the other group received 250 mg metformin pill thrice a day for the duration of the experiment. After three months of medication treatment, the patients were contacted for a follow-up, and all of their baseline measures were retaken. Comparisons between baseline and post-treatment BMI were made. Student & independent sample t-test was applied. P-value 0.05 was deemed significant. Results: The research comprised a total of 152 patients. Patients were an average of 27.4 years old, with a standard deviation of 7.6. Significantly better efficacy of my-inositol in terms of BMI (t= -9.89, P=0.000, C.I=95% ) than Metformin in polycystic ovary syndrome patients was found. Conclusion: Myo-inositol was more effective than Metformin at reducing BMI consistently in polycystic ovary syndrome.